期刊文献+

双源CT双能量虚拟平扫在肝脏常见良性病变诊断中的价值 被引量:1

The Analysis of Value of Dual Energy Virtual Dual Energy CT Scan in the Diagnosis of Common Benign Liver Diseases
下载PDF
导出
摘要 目的:探讨双源CT双能量虚拟平扫在肝脏常见良性病变诊断中的价值。方法:选取126例上腹部病变患者为研究对象,均采用双源CT进行常规平扫结合增强扫描并双能量扫描,以CT平扫结合增强扫描为参照标准,比较分析单纯平扫与虚拟平扫的诊断情况及不同扫描模式对患者的辐射量。结果:126例行腹部CT扫描的患者中,经CT平扫结合增强扫描诊断共检出存在肝脏良性病变者66例(共109处病变),包括肝囊肿41处,肝内胆管结石或肝脏钙化灶32处,肝血管瘤15处,脂肪肝13处,炎性假瘤8处。在胆管结石或肝脏钙化灶检出率方面,常规平扫高于虚拟平扫,差异有统计学意义(P<0.05),而在肝囊肿、肝血管瘤、脂肪肝及炎性假瘤的检出率方面,常规平扫与虚拟平扫的检出率,差异无统计学意义(P>0.05);在患者接受的辐射剂量方面,双能模式扫描时患者接受的CT容积剂量指数、剂量长度乘积及有效剂量均明显少于单能模式扫描,比较差异均有统计学意义(P<0.05)。结论:CT虚拟平扫在肝囊肿、肝血管瘤、脂肪肝及炎性假瘤的检出率方面与CT平扫基本相当,且该扫描方式对患者的辐射剂量显著低于CT平扫,在肝脏良性病变诊断中有较高的潜在应用价值。
作者 魏冰 WEI Bing
出处 《山西职工医学院学报》 CAS 2019年第3期71-73,共3页 Journal of Shanxi Medical College for Continuing Education
  • 相关文献

参考文献7

二级参考文献65

  • 1Giovan Giuseppe Di Costanzo,Raffaella Tortora,Luca Iodice,Alfonso Galeota Lanza,Filippo Lampasi,Maria Teresa Tartaglione,Francesco Paolo Picciotto,Silvana Mattera,Massimo De Luca.Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice[J]. Digestive and Liver Disease . 2012 (9)
  • 2Therasse P,Arbuck S G,Eisenhauer E A,Wanders J,Kaplan R S,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom A T,Christian M C,Gwyther S G.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute . 2000
  • 3Giuseppe Salvaggio,Alessandro Furlan,Francesco Agnello,Giuseppe Cabibbo,Daniele Marin,Lydia Giannitrapani,Chiara Genco,Massimo Midiri,Roberto Lagalla,Giuseppe Brancatelli.Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results[J]. La radiologia medica . 2014 (4)
  • 4Nicolas Widmer,Christophe Bardin,Etienne Chatelut,Angelo Paci,Jos Beijnen,Dominique Levêque,Gareth Veal,Alain Astier.Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies[J]. European Journal of Cancer . 2014
  • 5Maria Reig,Ferran Torres,Carlos Rodriguez-Lope,Alejandro Forner,Neus LLarch,Jordi Rimola,Anna Darnell,José Ríos,Carmen Ayuso,Jordi Bruix.Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib[J]. Journal of Hepatology . 2014
  • 6Zocco Maria Assunta,Garcovich Matteo,Lupascu Andrea,Di Stasio Enrico,Roccarina Davide,Annicchiarico Brigida Elenora,Riccardi Laura,Ainora Maria Elena,Ponziani Francesca,Caracciolo Gianluigi,Rapaccini Gian Lodovico,Landolfi Raffaele,Siciliano Massimo,Pompili Maurizio,Gasbarrini Antonio.Early prediction of response to Sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound[J]. Journal of Hepatology . 2013
  • 7Takahide Nakazawa,Hisashi Hidaka,Juichi Takada,Yusuke Okuwaki,Yoshiaki Tanaka,Masaaki Watanabe,Akitaka Shibuya,Tsutomu Minamino,Shigehiro Kokubu,Wasaburo Koizumi.Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib[J]. European Journal of Gastroenterology & Hepatology . 2013 (6)
  • 8Haeryoung Kim,Jeong Eun Yoo,Jai Young Cho,Bong-Kyeong Oh,Yoo-Seok Yoon,Ho-Seong Han,Hye Seung Lee,Ja June Jang,Sook Hyang Jeong,Jin Wook Kim,Young Nyun Park.Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing “stemness”-related markers<!-- Doctopic: CAN -->[J]. Journal of Hepatology . 2013
  • 9Katsutoshi Sugimoto,Fuminori Moriyasu,Kazuhiro Saito,Nicolas Rognin,Naohisa Kamiyama,Yoshihiro Furuichi,Yasuharu Imai.Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US[J]. Liver Int . 2013 (4)
  • 10Nicola Personeni,Silvia Bozzarelli,Tiziana Pressiani,Lorenza Rimassa,Maria Chiara Tronconi,Francesco Sclafani,Carlo Carnaghi,Vittorio Pedicini,Laura Giordano,Armando Santoro.Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma[J]. Journal of Hepatology . 2012 (1)

共引文献75

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部